SOL Global (CSE:SOL) Completes Share Consolidation

January 14, 2026 — Leads & Copy — SOL Global Investments Corp. has completed a share consolidation following approval by its Board of Directors.

The consolidation, based on ten pre-consolidation common shares for one post-consolidation common share, was previously announced on December 8, 2025, and approved by shareholders at the annual general and special meeting on February 21, 2025.

As a result of the consolidation, the company now has approximately 22,999,723 post-consolidation common shares outstanding, down from 229,997,433 pre-consolidation common shares.

The company’s name and trading symbol will remain the same. Trading of the post-consolidation common shares commenced on January 14, 2026.

Outstanding deferred share units and share purchase warrants have been proportionately adjusted to maintain their economic equivalence.

Registered shareholders holding pre-consolidation common shares in certificated form will receive letters of transmittal with instructions for exchanging their existing share certificates for new post-consolidation share certificates. Shareholders holding shares through a broker will have their accounts automatically updated. Registered shareholders with holdings represented by a DRS statement will receive a new post-consolidation DRS statement.

The new CUSIP number for the post-consolidation common shares is 78471G407, and the new ISIN number is CA78471G4079. Fractional shares resulting from the consolidation have been rounded down, and no cash consideration will be paid for them.

SOL Global is focused on digital assets, aiming to provide public exposure to ecosystems through token acquisitions, staking for yield generation, and investments in early-stage protocols.

Davide Marcotti, President & Chief Executive Officer of SOL Global Investments Corp., can be contacted at (212) 729-9208 or info@solglobal.com for further information.

Source: SOL Global Investments Corp.

×

Welcome!

Biotech Reporter is the source most up-to-date real-time, direct-from-source News Tips and Story Leads.

By Subscribing you will receive Daily Biotech Update each day at 9:30 am ET (Market Open) in your inbox and you can unsubscribe any time.